U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H28NO3
Molecular Weight 354.4626
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of BEVONIUM

SMILES

C[N+]1(C)CCCCC1COC(=O)C(O)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=UHUMRJKDOOEQIG-UHFFFAOYSA-N
InChI=1S/C22H28NO3/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3/q+1

HIDE SMILES / InChI

Description

Bevonium is a parasympatolytic antimuscarinic compound. It possesses spasmolytic properties. The use of the drug is discontinued.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACABEL

PubMed

Sample Use Guides

In Vivo Use Guide
Form of release of medicine: Acabel: tablets on 50 mg, candles on 30 pieces in packaging. Acabel compositum: tablets (bevonium methyl sulfate — 0,05 g, Dipyronum — 0,25 g); candles (bevonium methyl sulfate — 0,03 g, Dipyronum — 1 g); ampoules on 5 ml (bevonium methyl sulfate — 0,0025 g, Dipyronum — 2,5 g). Use: Acabel appoint inside 1 — 2 tablet 2 — 3 times a day, candles (only the adult) — on 1 piece 2 — 3 times a day. Intramusculary or intravenously slowly enter on 1/2 — 1 ampoule of an akabel difficult 3 once a day.
Route of Administration: Other
In Vitro Use Guide
Unknown